{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:30:17Z","timestamp":1790656217954,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"University Cooperation and Public Health Collaborative Innovation Project of Anhui Provincial Department of Education","award":["GXXT-2020-016"],"award-info":[{"award-number":["GXXT-2020-016"]}]},{"name":"Anhui Institute of Translational Medicine","award":["2021zhyx-C55"],"award-info":[{"award-number":["2021zhyx-C55"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of this study was to investigate the association of serum carcinoembryonic antigen (CEA), nerve-specific enolase (NSE), cytokeratin 19 fragment (CYFRA21-1), squamous cell carcinoma antigen (SCC-Ag), and pro-gastrin-releasing peptide (ProGRP) with the clinicopathological characteristics and chemotherapeutic outcomes of patients with lung cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 189 patients with lung cancer (lung cancer group) diagnosed at the Fourth Affiliated Hospital of Anhui Medical University from January 2020 to December 2021 were included. During the same period, 199 patients with benign lung disorders were included as the benign lung disease group and 75 healthy people were selected as the control group. The serum concentrations of CEA, NSE, CYFRA21-1, SCC-Ag, and ProGRP in all the 3 groups were analyzed and compared in patients with different lung cancer tumor-node-metastasis (TNM) stages and pathological classifications. A\u00a0total of 11 patients with small cell lung cancer (SCLC) and 18 patients with lung adenocarcinoma (LAC) were further evaluated for\u00a0the dynamic changes of CEA, NSE, CYFRA21-1, SCC-Ag, and ProGRP before chemotherapy and during the 6 courses of chemotherapy, and the outcome of chemotherapy was evaluated every 2 courses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The serum concentrations of CEA, NSE, CYFRA21-1, SCC-Ag, and ProGRP in the lung cancer group were significantly higher than those in the control group (P\u2005&amp;lt;\u2005.05). We found statistically significant differences in serum CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP among patients with different pathological types (LAC, squamous cell carcinoma, or SCLC) and different stages (I\u2013IV). The ProGRP and NSE had the highest expression in SCLC, CEA showed the highest expression in LAC, whereas CYFRA21-1 and SCC-Ag showed the highest expression in lung squamous cell carcinoma (LSCC). The concentrations of all the markers were elevated in the advanced pathological stages. The receiver operating characteristic curve analysis showed that the diagnostic value of the combined detection of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP for lung cancer was significantly higher than using a single biomarker (P\u2005&amp;lt;\u2005.05). Our dynamic monitoring results show that ProGRP progressively decreased in remission cases of SCLC and CEA progressively decreased in LAC remission cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP have good clinical value in the early diagnosis, differential diagnosis, and progression monitoring of lung cancer. The ProGRP and CEA concentrations are beneficial for evaluating the outcome of chemotherapy in SCLC and LAC. The combined detection of multiple biomarkers shows improved clinical value in the early diagnosis of lung cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmac122","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T17:52:09Z","timestamp":1666720329000},"page":"372-379","source":"Crossref","is-referenced-by-count":38,"title":["Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer"],"prefix":"10.1093","volume":"54","author":[{"given":"Huijuan","family":"Bi","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District , Hefei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District , Hefei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District , Hefei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District , Hefei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District , Hefei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilu","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Anhui Public Health Clinical Center, The First Affiliated Hospital of Anhui Medical University North District , Hefei , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"2023070507325979600_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung cancer 2020: epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin Chest Med."},{"issue":"1","key":"2023070507325979600_CIT0002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/CCO.0000000000000703","article-title":"Lung cancer in China: current and prospect","volume":"33","author":"Wu","year":"2021","journal-title":"Curr Opin Oncol."},{"issue":"16","key":"2023070507325979600_CIT0003","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.3390\/ijms22168661","article-title":"Current and future development in lung cancer diagnosis","volume":"22","author":"Nooreldeen","year":"2021","journal-title":"Int J Mol Sci ."},{"issue":"1","key":"2023070507325979600_CIT0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.hoc.2016.08.006","article-title":"Lung cancer biomarkers","volume":"31","author":"Villalobos","year":"2017","journal-title":"Hematol Oncol Clin North Am."},{"key":"2023070507325979600_CIT0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/bs.pmbts.2018.12.011","article-title":"Serum CEA levels in 49 different types of cancer and noncancer diseases","volume":"162","author":"Hao","year":"2019","journal-title":"Prog Mol Biol Transl Sci."},{"issue":"2","key":"2023070507325979600_CIT0006","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.lungcan.2011.11.012","article-title":"Carcinoembryonic antigen (CEA) as tumor marker in lung cancer","volume":"76","author":"Grunnet","year":"2012","journal-title":"Lung Cancer."},{"issue":"16","key":"2023070507325979600_CIT0007","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.7150\/ijms.58415","article-title":"NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process","volume":"18","author":"Lu","year":"2021","journal-title":"Int J Med Sci."},{"key":"2023070507325979600_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1177271917751608","article-title":"Evaluation of a serum lung cancer biomarker panel","volume":"13","author":"Mazzone","year":"2018","journal-title":"Biomark Insights."},{"key":"2023070507325979600_CIT0009","doi-asserted-by":"crossref","first-page":"6929971","DOI":"10.1155\/2021\/6929971","article-title":"Impact of HSP90\u03b1, CEA, NSE, SCC, and CYFRA21-1 on lung cancer patients","volume":"2021","author":"Zhou","year":"2021","journal-title":"J Healthc Eng"},{"key":"2023070507325979600_CIT0010","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cca.2021.06.013","article-title":"Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma","volume":"520","author":"Zheng","year":"2021","journal-title":"Clin Chim Acta."},{"issue":"11","key":"2023070507325979600_CIT0011","article-title":"Diagnostic value and clinical significance of combined detection","volume":"66","author":"Li","year":"2020","journal-title":"Clin Lab."},{"issue":"9","key":"2023070507325979600_CIT0012","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00595-017-1477-y","article-title":"History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer","volume":"47","author":"Nakamura","year":"2017","journal-title":"Surg Today."},{"key":"2023070507325979600_CIT0013","first-page":"231","article-title":"Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response","volume":"8","author":"Wojcik","year":"2017","journal-title":"Lung Cancer (Auckl)."},{"issue":"4","key":"2023070507325979600_CIT0014","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.21037\/jtd.2019.04.29","article-title":"Diagnostic value of ProGRP for small cell lung cancer in different stages","volume":"11","author":"Dong","year":"2019","journal-title":"J Thorac Dis"},{"key":"2023070507325979600_CIT0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clinbiochem.2018.05.001","article-title":"Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer","volume":"58","author":"Korkmaz","year":"2018","journal-title":"Clin Biochem."},{"issue":"4","key":"2023070507325979600_CIT0016","first-page":"257","article-title":"Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2019 edition)]","volume":"42","author":"Chinese Medical Association; Oncology Society of Chinese Medical Association; Chinese Medical Association Publishing House","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi."},{"issue":"12","key":"2023070507325979600_CIT0017","first-page":"881","article-title":"Nouvelles recommandations pour l\u2019\u00e9valuation de la r\u00e9ponse tumorale dans les tumeurs solides [New guidelines to evaluate the response to treatment in solid tumors]","volume":"87","author":"Duffaud","year":"2000","journal-title":"Bull Cancer."},{"issue":"1","key":"2023070507325979600_CIT0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1759-7714.12916","article-title":"Epidemiology of lung cancer in China","volume":"10","author":"Cao","year":"2019","journal-title":"Thorac Cancer."},{"key":"2023070507325979600_CIT0019","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2019.10.009","article-title":"Epidemiology of lung cancer and lung cancer screening programs in China and the United States","volume":"468","author":"Yang","year":"2020","journal-title":"Cancer Lett"},{"issue":"10","key":"2023070507325979600_CIT0020","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jtho.2020.04.028","article-title":"Lung Cancer in People\u2019s Republic of China","volume":"15","author":"Gao","year":"2020","journal-title":"J Thorac Oncol."},{"issue":"6","key":"2023070507325979600_CIT0021","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/RCT.0000000000001204","article-title":"The past, present, and future (liquid biopsy) of serum tumor markers in lung cancer: a primer for the radiologist","volume":"45","author":"Vos","year":"2021","journal-title":"J Comput Assist Tomogr."},{"issue":"1","key":"2023070507325979600_CIT0022","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12967-019-1828-0","article-title":"The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to nivolumab in advanced non-small cell lung cancer (NSCLC) patients","volume":"17","author":"Dal\u00a0Bello","year":"2019","journal-title":"J Transl Med."},{"issue":"8","key":"2023070507325979600_CIT0023","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/cam4.2286","article-title":"Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med."},{"key":"2023070507325979600_CIT0024","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2018.03.015","article-title":"The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)","volume":"120","author":"Muley","year":"2018","journal-title":"Lung Cancer."},{"issue":"3","key":"2023070507325979600_CIT0025","first-page":"774","article-title":"Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors","volume":"49","author":"Tutar","year":"2019","journal-title":"Turk J Med Sci."},{"issue":"3","key":"2023070507325979600_CIT0026","article-title":"The serum tumor markers in combination for clinical diagnosis of lung cancer","volume":"66","author":"Wu","year":"2020","journal-title":"Clin Lab."},{"issue":"4","key":"2023070507325979600_CIT0027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/17246008211049446","article-title":"The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination","volume":"36","author":"Chen","year":"2021","journal-title":"Int J Biol Markers."},{"key":"2023070507325979600_CIT0028","doi-asserted-by":"crossref","first-page":"9","DOI":"10.33393\/jcb.2021.2212","article-title":"Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring","volume":"10","author":"Barchiesi","year":"2021","journal-title":"J Circ Biomark."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/54\/4\/372\/50781402\/lmac122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/54\/4\/372\/50781402\/lmac122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T16:47:14Z","timestamp":1688575634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/54\/4\/372\/6772479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,25]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmac122","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,10,25]]}}}